Skip to main content
Erschienen in: Journal of Neurology 6/2018

29.03.2018 | Original Communication

Supervised versus unsupervised technology-based levodopa monitoring in Parkinson’s disease: an intrasubject comparison

verfasst von: Giovanna Lopane, Sabato Mellone, Mattia Corzani, Lorenzo Chiari, Pietro Cortelli, Giovanna Calandra-Buonaura, Manuela Contin

Erschienen in: Journal of Neurology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

We aimed to assess the intrasubject reproducibility of a technology-based levodopa (LD) therapeutic monitoring protocol administered in supervised versus unsupervised conditions in patients with Parkinson’s disease (PD). The study design was pilot, intrasubject, single center, open and prospective. Twenty patients were recruited. Patients performed a standardized monitoring protocol instrumented by an ad hoc embedded platform after their usual first morning LD dose in two different randomized ambulatory sessions: one under a physician’s supervision, the other self-administered. The protocol is made up of serial motor and non-motor tests, including alternate finger tapping, Timed Up and Go test, and measurement of blood pressure. Primary motor outcomes included comparisons of intrasubject LD subacute motor response patterns over the 3-h test in the two experimental conditions. Secondary outcomes were the number of intrasession serial test repetitions due to technical or handling errors and patients’ satisfaction with the unsupervised LD monitoring protocol. Intrasubject LD motor response patterns were concordant between the two study sessions in all patients but one. Platform handling problems averaged 4% of total planned serial tests for both sessions. Ninety-five percent of patients were satisfied with the self-administered LD monitoring protocol. To our knowledge, this study is the first to explore the potential of unsupervised technology-based objective motor and non-motor tasks to monitor subacute LD dosing effects in PD patients. The results are promising for future telemedicine applications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J et al (2016) Movement disorders society task force on technology technology in Parkinson’s disease: challenges and opportunities. Mov Disord 31:1272–1282CrossRefPubMedPubMedCentral Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J et al (2016) Movement disorders society task force on technology technology in Parkinson’s disease: challenges and opportunities. Mov Disord 31:1272–1282CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Maetzler W, Klucken J, Horne M (2016) A clinical view on the development of technology-based tools in managing Parkinson’s disease. Mov Disord 31:1263–1271CrossRefPubMed Maetzler W, Klucken J, Horne M (2016) A clinical view on the development of technology-based tools in managing Parkinson’s disease. Mov Disord 31:1263–1271CrossRefPubMed
3.
Zurück zum Zitat Dorsey ER, Vlaanderen FP, Engelen LJ, Kieburtz K, Zhu W, Biglan KM, Faber MJ, Bloem BR (2016) Moving Parkinson care to the home. Mov Disord 31:1258–1262CrossRefPubMedPubMedCentral Dorsey ER, Vlaanderen FP, Engelen LJ, Kieburtz K, Zhu W, Biglan KM, Faber MJ, Bloem BR (2016) Moving Parkinson care to the home. Mov Disord 31:1258–1262CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Homann CN, Suppan K, Wenzel K, Giovannoni G, Ivanic G, Horner S, Ott E, Hartung HP (2000) The bradykinesia akinesia incoordination test (BRAIN TEST), an objective and user-friendly means to evaluate patients with parkinsonism. Mov Disord 15:641–647CrossRefPubMed Homann CN, Suppan K, Wenzel K, Giovannoni G, Ivanic G, Horner S, Ott E, Hartung HP (2000) The bradykinesia akinesia incoordination test (BRAIN TEST), an objective and user-friendly means to evaluate patients with parkinsonism. Mov Disord 15:641–647CrossRefPubMed
5.
Zurück zum Zitat Pal PK, Lee CS, Samii A, Schulzer M, Stoessl AJ, Mak EK, Wudel J, Dobko T, Tsui JK (2001) Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson’s disease and correlates with PET. Parkinsonism Relat Disord 7:305–309CrossRefPubMed Pal PK, Lee CS, Samii A, Schulzer M, Stoessl AJ, Mak EK, Wudel J, Dobko T, Tsui JK (2001) Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson’s disease and correlates with PET. Parkinsonism Relat Disord 7:305–309CrossRefPubMed
6.
Zurück zum Zitat Taylor Tavares AL, Jefferis GS, Koop M, Hill BC, Hastie T, Heit G, Bronte-Stewart HM (2005) Quantitative measurements of alternate finger tapping in Parkinson’s disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation. Mov Disord 20:1286–1298CrossRefPubMed Taylor Tavares AL, Jefferis GS, Koop M, Hill BC, Hastie T, Heit G, Bronte-Stewart HM (2005) Quantitative measurements of alternate finger tapping in Parkinson’s disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation. Mov Disord 20:1286–1298CrossRefPubMed
7.
Zurück zum Zitat Podsiadlo D, Richardson S (1991) The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39:142–148CrossRefPubMed Podsiadlo D, Richardson S (1991) The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39:142–148CrossRefPubMed
8.
Zurück zum Zitat Contin M, Riva R, Martinelli P, Procaccianti G, Cortelli P, Avoni P, Baruzzi A (1990) Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 13:19–28CrossRefPubMed Contin M, Riva R, Martinelli P, Procaccianti G, Cortelli P, Avoni P, Baruzzi A (1990) Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 13:19–28CrossRefPubMed
9.
Zurück zum Zitat Contin M, Riva R, Martinelli P, Albani F, Avoni P, Baruzzi A (2001) Levodopa therapy monitoring in patients with Parkinson’s disease: a kinetic–dynamic approach. Ther Drug Monit 23:621–629CrossRefPubMed Contin M, Riva R, Martinelli P, Albani F, Avoni P, Baruzzi A (2001) Levodopa therapy monitoring in patients with Parkinson’s disease: a kinetic–dynamic approach. Ther Drug Monit 23:621–629CrossRefPubMed
10.
Zurück zum Zitat Calandra-Buonaura G, Doria A, Lopane G, Guaraldi P, Capellari S, Martinelli P, Cortelli P, Contin M (2016) Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson’s disease. J Neurol 263:250–256CrossRefPubMed Calandra-Buonaura G, Doria A, Lopane G, Guaraldi P, Capellari S, Martinelli P, Cortelli P, Contin M (2016) Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson’s disease. J Neurol 263:250–256CrossRefPubMed
11.
Zurück zum Zitat Lang AE, Marras C (2014) Initiating dopaminergic treatment in Parkinson’s disease. Lancet 384:1164–1166CrossRefPubMed Lang AE, Marras C (2014) Initiating dopaminergic treatment in Parkinson’s disease. Lancet 384:1164–1166CrossRefPubMed
13.
Zurück zum Zitat Lopane G, Mellone S, Chiari L, Cortelli P, Calandra-Buonaura G, Contin M (2015) Dyskinesia detection and monitoring by a single sensor in patients with Parkinson’s Disease. Mov Disord 30:1267–1271CrossRefPubMed Lopane G, Mellone S, Chiari L, Cortelli P, Calandra-Buonaura G, Contin M (2015) Dyskinesia detection and monitoring by a single sensor in patients with Parkinson’s Disease. Mov Disord 30:1267–1271CrossRefPubMed
14.
Zurück zum Zitat Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson’s disease. Arch Neurol 56:33–39CrossRefPubMed Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson’s disease. Arch Neurol 56:33–39CrossRefPubMed
15.
Zurück zum Zitat Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18:738–750CrossRef Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18:738–750CrossRef
16.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189–198CrossRef Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189–198CrossRef
17.
Zurück zum Zitat Taylor JP, Rowan EN, Lett D, O’Brien JT, McKeith IG, Burn DJ (2008) Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype. J Neurol Neurosurg Psychiatry 79:1318–1323CrossRefPubMed Taylor JP, Rowan EN, Lett D, O’Brien JT, McKeith IG, Burn DJ (2008) Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype. J Neurol Neurosurg Psychiatry 79:1318–1323CrossRefPubMed
18.
Zurück zum Zitat Irwin RP, Nutt JG, Woodward WR, Gancher ST (1992) Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients. Clin Neuropharmacol 15:365–374CrossRefPubMed Irwin RP, Nutt JG, Woodward WR, Gancher ST (1992) Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients. Clin Neuropharmacol 15:365–374CrossRefPubMed
19.
Zurück zum Zitat Hagell P, Widner H (1999) Clinical rating of dyskinesias in Parkinson’s disease: use and reliability of a new rating scale. Mov Disord 14:448–455CrossRefPubMed Hagell P, Widner H (1999) Clinical rating of dyskinesias in Parkinson’s disease: use and reliability of a new rating scale. Mov Disord 14:448–455CrossRefPubMed
20.
Zurück zum Zitat Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clark CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 15:2649–2653CrossRef Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clark CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 15:2649–2653CrossRef
21.
Zurück zum Zitat Stocchi F, Jenner P, Obeso JA (2010) When do levodopa motor fluctuations first appear in Parkinson’s disease? Eur Neurol 63:257–266CrossRefPubMed Stocchi F, Jenner P, Obeso JA (2010) When do levodopa motor fluctuations first appear in Parkinson’s disease? Eur Neurol 63:257–266CrossRefPubMed
22.
Zurück zum Zitat Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ (2010) The clinically important difference on the Unified Parkinson’s disease Rating Scale. Arch Neurol 67:64–70CrossRefPubMed Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ (2010) The clinically important difference on the Unified Parkinson’s disease Rating Scale. Arch Neurol 67:64–70CrossRefPubMed
23.
Zurück zum Zitat Arora S, Venkataraman V, Zhan A, Donohue S, Biglan KM, Dorsey ER, Little MA (2015) Detecting and monitoring the symptoms of Parkinson’s disease using smartphones: a pilot study. Parkinsonism Relat Disord 21:650–653CrossRefPubMed Arora S, Venkataraman V, Zhan A, Donohue S, Biglan KM, Dorsey ER, Little MA (2015) Detecting and monitoring the symptoms of Parkinson’s disease using smartphones: a pilot study. Parkinsonism Relat Disord 21:650–653CrossRefPubMed
25.
Zurück zum Zitat Maetzler W, Rochester L (2015) Body-worn sensors—the brave new world of clinical measurement? Mov Disord 30:1203–1205CrossRefPubMed Maetzler W, Rochester L (2015) Body-worn sensors—the brave new world of clinical measurement? Mov Disord 30:1203–1205CrossRefPubMed
27.
Zurück zum Zitat Artusi CA, Mishra M, Latimer P, Vizcarra JA, Lopiano L, Maetzler W, Merola A, Espay AJ (2018) Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. Parkinsonism Relat Disord 46(Suppl 1):S53–S56CrossRefPubMed Artusi CA, Mishra M, Latimer P, Vizcarra JA, Lopiano L, Maetzler W, Merola A, Espay AJ (2018) Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. Parkinsonism Relat Disord 46(Suppl 1):S53–S56CrossRefPubMed
Metadaten
Titel
Supervised versus unsupervised technology-based levodopa monitoring in Parkinson’s disease: an intrasubject comparison
verfasst von
Giovanna Lopane
Sabato Mellone
Mattia Corzani
Lorenzo Chiari
Pietro Cortelli
Giovanna Calandra-Buonaura
Manuela Contin
Publikationsdatum
29.03.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 6/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-018-8848-1

Weitere Artikel der Ausgabe 6/2018

Journal of Neurology 6/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.